The patents at issue were five patents Teva had listed in the Orange Book for its ProAir® HFA (albuterol sulfate) Inhalation Aerosol. The patents are described in the Federal Circuit opinion as ...

The Federal Trade Commission (FTC) has continued its scrutiny of Orange Book listings for device patents, signaling bipartisan concern over potential anti-competitive practices. Actions taken by the ...

Pharmaceutical companies layer on patents for drug delivery devices to maintain market exclusivity, according to a new study.

“There is no dispute that the Inhaler Patents contain no claim for the active ingredient at issue, albuterol sulfate. Amneal contends that the Inhaler Patents do not meet the requirement that they ...

“Reference biologic drug makers until recently faced no obligation to disclose to the public the patents associated with their licensed biologic products…. This disparity between the Hatch-Waxman and ...